2023
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Kristensen L, Strober B, Poddubnyy D, Leung Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman D. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic Advances In Musculoskeletal Disease 2023, 15: 1759720x221149965. PMID: 36777695, PMCID: PMC9909057, DOI: 10.1177/1759720x221149965.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsAtherosclerotic CV diseaseTofacitinib-treated patientsAdverse cardiovascular eventsCV diseaseASCVD riskHigh blood pressurePsoriatic arthritisHigh riskHeart-related problemsHigher baselineCardiovascular eventsBlood pressureRisk calculatorIncidence rateMore casesBaseline cardiovascular riskBaseline metabolic syndromeCardiovascular disease riskJanus kinase inhibitorDose of tofacitinibGroup of conditionsBaseline MetSPsA trialsTofacitinib exposure
2016
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
Wu J, Strober B, Hansen P, Ahlehoff O, Egeberg A, Qureshi A, Robertson D, Valdez H, Tan H, Wolk R. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. Journal Of The American Academy Of Dermatology 2016, 75: 897-905. PMID: 27498960, DOI: 10.1016/j.jaad.2016.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureC-Reactive ProteinCardiovascular DiseasesCholesterolClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicComorbidityDyslipidemiasFemaleGlycated HemoglobinHumansMaleMetabolic SyndromeMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesRisk FactorsTreatment OutcomeTriglyceridesConceptsMajor adverse CV eventsCV risk factorsTotal/HDL cholesterol ratioEffects of tofacitinibHDL cholesterol ratioIncidence rateLow-density lipoproteinRisk factorsPlaque psoriasisCholesterol ratioLong-term extension dataC-reactive protein levelsHigh-density lipoprotein cholesterolAdverse CV eventsCardiovascular risk factorsSystemic inflammatory conditionsDose-dependent increaseCV eventsTofacitinib dosesCardiovascular outcomesLipoprotein cholesterolBlood pressureTofacitinib treatmentTotal cholesterolHemoglobin levels
2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis
Langley R, Papp K, Gottlieb A, Krueger G, Gordon K, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2012, 27: 1252-1261. PMID: 23157612, DOI: 10.1111/j.1468-3083.2012.04705.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Basal CellCarcinoma, Squamous CellCardiovascular DiseasesClinical Trials as TopicFemaleHumansInterleukin-12Interleukin-23MaleMiddle AgedPrevalencePsoriasisRandomized Controlled Trials as TopicSeverity of Illness IndexSkin Diseases, InfectiousSkin NeoplasmsTreatment OutcomeConceptsOpen-label extension studyMajor adverse cardiovascular eventsPotential safety signalsSevere psoriasisAdverse eventsParent studyClinical trialsSafety signalsSafety resultsAnti-IL-12/23 treatmentInterleukin-12/23 monoclonal antibodyOpen-label extension trialPhase IIAdverse cardiovascular eventsCardiovascular risk factorsBaseline blood pressureBody mass indexRate of infectionCardiovascular eventsFirst doseSafety findingsBlood pressureIL-12/23Mass indexExtension trial